1. Home
  2. SCNI vs MBIO Comparison

SCNI vs MBIO Comparison

Compare SCNI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCNI
  • MBIO
  • Stock Information
  • Founded
  • SCNI 2003
  • MBIO 2015
  • Country
  • SCNI Israel
  • MBIO United States
  • Employees
  • SCNI N/A
  • MBIO N/A
  • Industry
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCNI Health Care
  • MBIO Health Care
  • Exchange
  • SCNI Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • SCNI 4.6M
  • MBIO 4.7M
  • IPO Year
  • SCNI N/A
  • MBIO N/A
  • Fundamental
  • Price
  • SCNI $0.89
  • MBIO $1.17
  • Analyst Decision
  • SCNI
  • MBIO
  • Analyst Count
  • SCNI 0
  • MBIO 0
  • Target Price
  • SCNI N/A
  • MBIO N/A
  • AVG Volume (30 Days)
  • SCNI 53.1K
  • MBIO 84.3K
  • Earning Date
  • SCNI 11-24-2025
  • MBIO 11-07-2025
  • Dividend Yield
  • SCNI N/A
  • MBIO N/A
  • EPS Growth
  • SCNI N/A
  • MBIO N/A
  • EPS
  • SCNI 0.26
  • MBIO N/A
  • Revenue
  • SCNI $1,147,000.00
  • MBIO N/A
  • Revenue This Year
  • SCNI N/A
  • MBIO N/A
  • Revenue Next Year
  • SCNI N/A
  • MBIO N/A
  • P/E Ratio
  • SCNI $3.30
  • MBIO N/A
  • Revenue Growth
  • SCNI 303.87
  • MBIO N/A
  • 52 Week Low
  • SCNI $0.86
  • MBIO $0.89
  • 52 Week High
  • SCNI $6.18
  • MBIO $21.95
  • Technical
  • Relative Strength Index (RSI)
  • SCNI 30.08
  • MBIO 35.26
  • Support Level
  • SCNI $0.86
  • MBIO $1.14
  • Resistance Level
  • SCNI $1.04
  • MBIO $1.23
  • Average True Range (ATR)
  • SCNI 0.08
  • MBIO 0.08
  • MACD
  • SCNI -0.01
  • MBIO -0.00
  • Stochastic Oscillator
  • SCNI 9.07
  • MBIO 18.38

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: